攻克儿童ALL微小残留病:CD28 CAR-T与移植
该文评述Curran等在Blood发表的临床试验,评估第二代CD19 CAR-T治疗儿童及年轻成人复发/难治B-ALL。文章指出强化淋巴清除对疗效重要,CD28 CAR-T达MRD阴性后巩固性异基因移植可获可接受的长期无病生存,并补充了因脑水肿死亡而停止商业开发的CD28 CART19产品的临床数据。
要点
- 儿童及年轻成人复发/难治B-ALL中,CD28 CAR-T前强化淋巴清除有助于获得缓解。
- CD28 CAR-T达MRD阴性后行巩固性异基因移植,长期无病生存可接受。
- 该CD28 CART19产品因另一项药企试验中脑水肿死亡而停止商业开发。
核心结论
- 儿童及年轻成人复发/难治B-ALL中,CD28 CAR-T后达MRD阴性并桥接异基因移植可获可接受的长期无病生存。
研究设计与样本
- Curran等开展的临床试验,评估第二代CD19 CAR-T在儿童及年轻成人复发/难治B-ALL中的疗效。
主要发现
- 强化淋巴清除对CAR-T输注后获得缓解具有重要性。
- CD28 CAR-T达MRD阴性后行巩固性异基因移植,长期无病生存可接受。
- 该CD28 CART19产品因另一项药企试验中脑水肿死亡而停止商业开发。
临床怎么用
- 儿童及年轻成人复发/难治B-ALL可考虑CD28 CAR-T,输注前应强化淋巴清除。
- CAR-T达MRD阴性后可桥接巩固性异基因移植以改善长期无病生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this issue of Blood, Curran et al report clinical trial results evaluating a second-generation CD19-directed chimeric antigen receptor (CAR) T-cell therapy in pediatric and young adult (AYA) relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). Autologous CAR T-cell immunotherapies are revolutionizing the treatment of B-cell malignancies. CAR T-cell treatment involves genetic engineering of a patient’s T cells by insertion of a CAR construct, which upon expression, recognizes CD19 on neoplastic cells and triggers T-cell activation and tumor killing. The paper is notable for several reasons. First, it confirms in a pediatric population the importance of intensive lymphodepletion before CAR T-cell infusion to achieve responses. Second, in children treated with a CD28-based CAR T cell achieving minimal residual disease (MRD)− status, consolidative allogeneic transplant leads to acceptable long-term disease-free survival. Lastly, this report provides key additional clinical data on a CD28-based CART19 product whose commercial development was halted due to cerebral edema deaths during a separate pharma-sponsored trial.
引用
- Ruella M, Locke FL. Beat pediatric ALL MRD: CD28 CAR T and transplant. Blood. 2019. PMID: 31877213. doi:10.1182/blood.2019003821
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。